Although molecular alterations in HRR genes besides BRCA1/2 are less established surrogate markers for HRD, mutations in ATM and PALB2 but not in other HRR genes were shown to be associated with sensitivity to PARPi in prostate carcinoma in a phase 3 clinical trial (Hussain et al, 2020). The gene discussed is ATM; the disease is prostate carcinoma.